Off-Label Use of Atypical Antipsychotics: An Update
Results and Summary of Benefits: Atypical Antipsychotics for Generalized Anxiety Disorder
The effect of quetiapine on response rate, as measured with the HAM-A, was studied in 3 trials with a total of 2,437 patients and used for meta-analysis. Response on the HAM-A was found to be 1.26-fold more likely with quetiapine than with placebo (lying in a range from 1.02- to 1.56-fold). The response rate of one in eight treated patients is attributable to quetiapine. The results from one study each of olanzapine and risperidone were not statistically significantly different from placebo, but the evidence is insufficient to permit conclusions about the effects of these treatments. The conclusion from evidence to date is that quetiapine improves symptoms of generalized anxiety disorder. The strength of evidence in support of this conclusion is moderate.
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | GAD | generalized anxiety | quetiapine | olanzapine | risperidone | HAM-A
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.